SEBI

'You will vomit all that is required as always': NSE 'yogi' to MD & CEO
IANS -
It seems from the conversations that rather than seeking 'guidance' as Ramkrishna has claimed, the 'yogi' was dictating her. On SEBI norms on listing of stock exchanges, the 'unknown person', vide e-mail dated December 4, 2015, suggested Ramkrishna to approach the Finance Ministry, PMO, SEBI etc. for self-listing of NSE.
Mysterious Himalayan 'yogi' had been flagged in NSE co-location scam probe
IANS -
These include information on organisational structure, dividend scenario, financial results, human resource policy and related issues, response to regulator etc., shared with an unknown person by addressing her correspondence to the email id, during the period 2014 to 2016. NSE in its letter dated July 6, 2018 had drawn reference to the forensic investigation report of E&Y wherein E&Y upon examination of the matter concluded that the said person was Anand Subramanian.
Drawing less than Rs 15 lakh in 2013, Subramanian started getting Rs 4.21 cr in 2016 in NSE
IANS -
Subramanian was offered to join NSE in the role of Chief Strategic Advisor with effect from April 1, 2013. At that material point of time he was VP L&RSTS, a subsidiary of Balmer & Lawrie. His last drawn compensation was less than Rs 15 lakh per annum. The only person who interviewed Anand Subramanian for his appointment was Chitra Ramkrishna. There are no notings in the personnel file of Anand Subramanian in relation to his interview, an internal report found.
NSE ex-chief Ramakrishna under CBI scanner after damning SEBI report
IANS -
According to the report, she met this yogi on the banks of holy Ganga around 20 years ago, and since then she had been taking his advice in all her personal and professional matters. Asked to identify the holder of email-id '[email protected]', she said it was Siddha Purusha and she used to meet him only at holy places.
Newsmen Explainer | The fall and fall of ex NSE CEO Chitra Ramakrishna
Newsmen Business Desk -
Chitra Ramakrishna, the former Managing Director and Chief Executive Officer (CEO) of the National Stock Exchange (NSE), was once one of the most celebrated icons of the Indian stock market. But Ms. Ramakrishna has fallen from grace ever since she resigned from the NSE board over allegations of financial misconduct in 2016. Here’s an explainer detailing the rise and fall of Chitra Ramakrishna.
SEBI amends norms for winding up of Mutual Fund schemes
IANS -
Now, the trustees will have to give notice within one day, disclosing the circumstances leading to the winding up of the scheme to the regulator as well as two daily newspapers having pan-India circulation, a SEBI notification said. The move comes after the Supreme Court in July last year, in context of the winding-up of Franklin Templeton Mutual Fund's six debt schemes
PTC India, subsidiary's shares fall further as SEBI disallows immediate Board meet
IANS -
The allegations were raised by the independent directors against its financial lending unit -- PTC India Financial Services. PTC India Financial Services, a subsidiary of PTC India, is registered with the RBI as a non-banking financial company (NBFC). On Monday, PTC India settled 5.3 per cent down at Rs 89.40, whereas PTC India Financial Services fell 9.1 per cent to Rs 18.10.
SEBI tweaks lock-in period norms for anchor investors
IANS -
"The existing lock in of 30 days shall continue for 50 per cent of the portion allocated to anchor investor and for the remaining portion, lock in of 90 days from the date of allotment shall be applicable for all issues opening on or after April 1, 2022," the market regulator said in a statement.
New SEBI norms may impact capital raising plans of some unicorns
IANS -
Yash Ashar, Partner and Head, Capital Markets, Cyril Amarchand Mangaldas, said the companies impacted are particularly those which may not have any other use of capital and where the existing shareholders are not keen to sell.
CAIT urges SEBI to stop PharmEasy's IPO
IANS -
Citing a Delhi High Court order passed in 2018, the traders' body said that sale of medicines over the internet is not allowed. API Holdings, the parent company of the e-pharmacy firm PharmEasy has reportedly filed the 'Draft Red Herring Prospectus' to the market regulator recently.
Advertisement